Antibodies (Abs) containing two different antigen-binding sites in one molecule are called
bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal …

ABSTRACT A bispecific antibody (bsAb) is able to bind two different targets or two distinct
epitopes on the same target. Broadly speaking, bsAbs can include any single molecule …

Bispecific antibodies (BsAbs) are antibodies with two binding sites directed at two different
antigens or two different epitopes on the same antigen. The clinical therapeutic effects of …

During the past two decades we have seen a phenomenal evolution of bispecific antibodies
for therapeutic applications. The 'zoo'of bispecific antibodies is populated by many different …

Bispecific antibodies (bsAbs) combine specificities of two antibodies and simultaneously
address different antigens or epitopes. BsAbs with 'two-target'functionality can interfere with …

The term bispecific antibody (bsAb) is used to describe a large family of molecules designed
to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from …

Development of bispecific antibodies (BsAbs) as therapeutic agents has recently attracted
significant attention, and investments in this modality have been steadily increasing. This …

Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been
extensively explored in translational and clinical studies since they were first developed in …

Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve
the selectivity and efficacy of antibody-based treatment of human disease. Recent studies …

Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …